Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. (3rd April 2019)

• Record Type: Journal Article
• Authors: Ribaldone, Davide Giuseppe; Pellicano, Rinaldo; Vernero, Marta; Caviglia, Gian Paolo; Saracco, Giorgio Maria; Morino, Mario; Astegiano, Marco
• Is Part Of: Scandinavian journal of gastroenterology. Volume 54:Number 4(2019)
• Page Start: 407
• Page End: 413
• Publication Date: 2019-04-03
• Subjects: Anti-integrin -- biologics -- Crohn's disease -- inflammatory bowel disease -- ulcerative colitis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2019.1597159
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background: Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy. Aims: To collect all the published data about patients treated with dual biological therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 months and to pool the data about the effectiveness and safety. Methods: A MEDLINE, and Web of Science search of all studies published in English until 1 January 2019 was conducted. Results: We included 7 studies with a total of 18 patients. Fifteen patients were treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by Crohn's disease and 50% of patients were treated with an immunosuppressant drug or steroid too. A clinical improvement was obtained in 100% of patients, and an endoscopic improvement in 93% of patients. No serious adverse events were reported. Conclusions: The use of dual biological therapy is an attractive therapeutic option and may be an opportunity to better tailor and personalize the therapies for patients. Further studies, as randomized control trials, to provide comparative efficacy and safety endpoints of combination therapies, and to clarify potential advantages of combined biological therapies, are needed.